Results 21 to 30 of about 6,399,825 (302)
Dendritic cell (DC) vaccination can be an effective post-remission therapy for acute myeloid leukemia (AML). Yet, current DC vaccines do not encompass the ideal stimulatory triggers for innate gamma delta (γδ) T cell anti-tumor activity. Promoting type 1
Heleen H. Van Acker +10 more
doaj +1 more source
Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination [PDF]
Cancer vaccines can induce robust activation of tumor-specific CD8(+) T cells that can destroy tumors. Understanding the mechanism by which cancer vaccines work is essential in designing next-generation vaccines with more potent therapeutic activity.
Yared, Hailemichael, Willem W, Overwijk
openaire +2 more sources
Genomic Characterization of the Emerging Pathogen
Streptococcus pseudopneumoniae is a close relative of the major human pathogen S. pneumoniae. It is increasingly associated with lower-respiratory-tract infections (LRTI) and a high prevalence of antimicrobial resistance (AMR). S.
Geneviève Garriss +8 more
doaj +1 more source
Allogeneic tumor cell vaccines [PDF]
The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies. The development of novel immunotherapies has been bolstered by the discovery of tumor-associated antigens (TAAs), through gene sequencing and proteomics.
Sanjay, Srivatsan +6 more
openaire +2 more sources
Whole Tumor Cell Vaccines for Glioma Immunotherapy [PDF]
High-grade glioma is associated with an extremely poor prognosis despite standard treatment with surgery, radiotherapy and chemotherapy. There is a pressing need to develop more effective treatments. Recent advances in immunotherapy for solid cancers have invigorated the search for an effective immunotherapy for glioma.
Cameron S, Field +2 more
openaire +2 more sources
Background The capacity of cytomegalovirus (CMV) to elicit long-lasting strong T cell responses, and the ability to engineer the genome of this DNA virus positions CMV-based vaccine vectors highly suitable as a cancer vaccine platform.
Elham Beyranvand Nejad +8 more
doaj +1 more source
Summary: Hepatocellular carcinoma (HCC) is a fatal malignant tumor, but effective clinical interventions are limited. PLGA/PEI-mediated DNA vaccine encoding the dual targets of high-mobility group box 1 (HMGB1) or GPC3 was developed for HCC treatment ...
Xiaoqing Shi +8 more
doaj +1 more source
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer. [PDF]
Studies of patients with paraneoplastic neurologic disorders (PND) have revealed that apoptotic tumor serves as a potential potent trigger for the initiation of naturally occurring tumor immunity.
Mayu O Frank +10 more
doaj +1 more source
CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanoma. [PDF]
The Salmonella type III secretion system (T3SS) efficiently translocates heterologous proteins into the cytosol of eukaryotic cells. This leads to an antigen-specific CD8 T-cell induction in mice orally immunized with recombinant Salmonella. Recently, we
Jellbauer, Stefan +11 more
core +2 more sources
Background: Lynch syndrome is a genetic disease resulting from mismatch repair gene mutation. Vaccine therapy can enhance the immunogenicity of Lynch syndrome and improve the therapeutic efficacy of immunotherapy.
Kai Ye +4 more
doaj +1 more source

